These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 23565635)

  • 1. Will antirheumatic treatment improve cardiovascular outcomes in patients with rheumatoid arthritis?
    Pieringer H; Pichler M; Pohanka E; Hoppe UC
    Curr Pharm Des; 2014; 20(4):486-95. PubMed ID: 23565635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cardiovascular comorbidity and its risk factors in rheumatoid arthritis].
    Kleinert S; Krueger K
    Z Rheumatol; 2011 Aug; 70(6):464-72. PubMed ID: 21863467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis.
    Nurmohamed MT; van Halm VP; Dijkmans BA
    Drugs; 2002; 62(11):1599-609. PubMed ID: 12109923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases.
    Atzeni F; Turiel M; Caporali R; Cavagna L; Tomasoni L; Sitia S; Sarzi-Puttini P
    Autoimmun Rev; 2010 Oct; 9(12):835-9. PubMed ID: 20678592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of traditional therapies and biologics on cardiovascular diseases in rheumatoid arthritis.
    Boyer JF; Cantagrel A; Constantin A
    Curr Vasc Pharmacol; 2008 Jul; 6(3):218-27. PubMed ID: 18673161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis.
    Tocci G; Goletti D; Marino V; Matucci A; Milano GM; Cantini F; Scarpa R
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):55-61. PubMed ID: 27924645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
    Drakopoulou M; Soulaidopoulos S; Oikonomou G; Tousoulis D; Toutouzas K
    Curr Vasc Pharmacol; 2020; 18(5):488-506. PubMed ID: 32056527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis.
    Shen J; Shang Q; Tam LS
    Transl Res; 2016 Jan; 167(1):138-51. PubMed ID: 26051628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.
    Kang EH; Liao KP; Kim SC
    Curr Rheumatol Rep; 2018 May; 20(7):42. PubMed ID: 29846814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review.
    Giollo A; Bissell LA; Buch MH
    Expert Opin Drug Saf; 2018 Jul; 17(7):697-708. PubMed ID: 29871535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased cardiovascular risk in patients with rheumatoid arthritis: an overview.
    Puttevils D; De Vusser P; Geusens P; Dens J
    Acta Cardiol; 2014 Apr; 69(2):111-8. PubMed ID: 24783461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of rheumatoid arthritis].
    Bolten WW
    MMW Fortschr Med; 2008 Aug; 150(32-35):50-3; quiz 54. PubMed ID: 19006884
    [No Abstract]   [Full Text] [Related]  

  • 13. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
    Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Siu S; Kraft J; Lynde C; Pope J; Gulliver W; Keeling S; Dutz J; Bessette L; Bissonnette R; Haraoui B
    Ann Rheum Dis; 2015 Mar; 74(3):480-9. PubMed ID: 25561362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment.
    Fragoulis GE; Panayotidis I; Nikiphorou E
    Curr Vasc Pharmacol; 2020; 18(5):431-446. PubMed ID: 31258091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular surface findings in patients with rheumatoid arthritis under methotrexate or biological agent therapy.
    Sevimli N; Karadag R; Madenci E; Bayramlar H; Arslan P; Ocal A; Dag Y
    Cutan Ocul Toxicol; 2017 Mar; 36(1):48-51. PubMed ID: 26878896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy.
    Galarraga B; Belch JJ; Pullar T; Ogston S; Khan F
    J Rheumatol; 2010 Mar; 37(3):521-8. PubMed ID: 20080919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis.
    Toussirot É
    Expert Opin Drug Saf; 2015 Apr; 14(4):525-32. PubMed ID: 25599626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of rheumatoid arthritis.
    Gaffo A; Saag KG; Curtis JR
    Am J Health Syst Pharm; 2006 Dec; 63(24):2451-65. PubMed ID: 17158693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNF as a Target of Inflammation in Rheumatoid Arthritis.
    Yamanaka H
    Endocr Metab Immune Disord Drug Targets; 2015; 15(2):129-34. PubMed ID: 25772178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of cardiovascular risk factors].
    Krüger K
    Z Rheumatol; 2016 Mar; 75(2):173-80; quiz 181-2. PubMed ID: 26924198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.